Dextrose Injection

Generic Name: dextrose monohydrate
Dosage Form: injection, solution

Dextrose Injection, USP
in AVIVA Plastic Container

Dextrose Injection Description

Dextrose Injection, USP is a sterile, nonpyrogenic solution for fluid replenishment and caloric supply in single dose containers for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, and caloric content are shown in Table 1.

Table 1
  Size
(mL)

*Dextrose Hydrous,

USP
(g/L)

Osmolarity
(mOsmol/L) (calc.)
pH nominal
(range)
Caloric Content
(kcal/L)
5% Dextrose Injection, USP 250
500
1000
50 252 4.5
(3.2 to 6.5)
170
10% Dextrose Injection, USP 250
500
1000
100 505 4.5
(3.2 to 6.5)
340

The flexible container is made with non-latex plastic materials specially designed for a wide range of parenteral drugs including those requiring delivery in containers made of polyolefins or polypropylene. For example, the AVIVA container system is compatible with and appropriate for use in the admixture and administration of paclitaxel. In addition, the AVIVA container system is compatible with and appropriate for use in the admixture and administration of all drugs deemed compatible with existing polyvinyl chloride container systems. The solution contact materials do not contain PVC, DEHP, or other plasticizers.

The suitability of the container materials has been established through biological evaluations, which have shown the container passes Class VI U.S. Pharmacopeia (USP) testing for plastic containers. These tests confirm the biological safety of the container system.

The flexible container is a closed system, and air is prefilled in the container to facilitate drainage. The container does not require entry of external air during administration.

The container has two ports: one is the administration outlet port for attachment of an intravenous administration set and the other port has a medication site for addition of supplemental medication (see Directions for Use). The primary function of the overwrap is to protect the container from the physical environment.

Dextrose Injection - Clinical Pharmacology

Dextrose Injection, USP has value as a source of water and calories. It is capable of inducing diuresis depending on the clinical condition of the patient.

Indications and Usage for Dextrose Injection

Dextrose Injection, USP is indicated as a source of water and calories.

Contraindications

Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Warnings

Dextrose Injection, USP should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis.

The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutive states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.

Excessive administration of Dextrose Injections may result in significant hypokalemia.

In very low birth weight infants, excessive or rapid administration of Dextrose Injection may result in increased serum osmolality and possible intracerebral hemorrhage.

Precautions

General

Do not connect flexible plastic containers of intravenous solutions in series connections. Such use could result in air embolism due to residual air being drawn from one container before administration of the fluid from a secondary container is completed.

Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

Dextrose Injection, USP should be used with caution in patients with overt or subclinical diabetes mellitus.

Laboratory Tests

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Drug Interactions

Studies have not been conducted to evaluate additional drug/drug or drug/food interactions with Dextrose Injection, USP.

Carcinogenesis, mutagenesis, impairment of fertility

Studies with Dextrose Injection, USP have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

Pregnancy

Teratogenic Effects

Pregnancy Category C.

Animal reproduction studies have not been conducted with Dextrose Injection, USP. It is also not known whether Dextrose Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose Injection, USP should be given to a pregnant woman only if clearly needed.

Labor and Delivery

Studies have not been conducted to evaluate the effects of Dextrose Injection, USP on labor and delivery. Caution should be exercised when administering this drug during labor and delivery.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dextrose Injection, USP is administered to a nursing mother.

Pediatric Use:

Dextrose Injection, USP is safe and effective for the stated indications in pediatric patients (see Indications and Usage).

Newborns – especially those born premature and with low birth weight - are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death.

Geriatric Use

Clinical studies of Dextrose Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Adverse Reactions

Hypersensitivity reactions, including anaphylaxis and chills.

Reactions which may occur because of the injection or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Dextrose Injection Dosage and Administration

As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Do not administer unless solution is clear and seal is intact.

All injections in AVIVA plastic containers are intended for intravenous administration using sterile equipment.

The dosage selection and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/ hypoglycemia. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.

Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.

How is Dextrose Injection Supplied

Dextrose Injection, USP in AVIVA plastic container is available as follows:

Code Size (ml) NDC Product Name
6E0062 250 0338-6346-02 5% Dextrose Injection, USP
6E0063 500 0338-6346-03  
6E0064 1000 0338-6346-04  
       
6E0162 250 0338-6347-02 10% Dextrose Injection, USP
6E0163 500 0338-6347-03  
6E0164 1000 0338-6347-04  

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25° C/ 77° F); brief exposure up to 40° C/ 104° F does not adversely affect the product.

DIRECTIONS FOR USE OF AVIVA PLASTIC CONTAINER

For Information on Risk of Air Embolism - see Precautions

To Open

Tear overwrap down side at slit and remove solution container. Moisture and some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow “To Add Medication” directions below.

Preparation for Administration

Caution: Do not use plastic containers in series connections.

Caution: Use only with a non-vented set or a vented set with the vent closed.

  1. Suspend container from eyelet support.
  2. Remove protector from outlet port at bottom of container.
  3. Attach administration set. Refer to complete directions accompanying set.

To Add Medication

Additives may be incompatible.

To add medication before solution administration

  1. Prepare medication site.
  2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
  3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

To add medication during solution administration

  1. Close clamp on the set.
  2. Prepare medication site.
  3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
  4. Remove container from IV pole and/or turn to an upright position.
  5. Evacuate both ports by squeezing them while container is in the upright position.
  6. Mix solution and medication thoroughly.
  7. Return container to in-use position and continue administration.

Baxter Healthcare Corporation
Deerfield, IL 60015 USA

Printed in USA

07-19-69-267
Rev. November 2013

Baxter and Aviva are trademarks of Baxter International Inc.

PRINCIPAL DISPLAY PANEL - PACKAGING LABELING

Container Label

LOT
EXP
250 mL
6E0062
NDC 0338-6346-02

5% Dextrose
Injection USP

Each 100 mL contains 5 g Dextrose
Hydrous USP pH 4.5 (3.2 to
6.5) Osmolarity 252 mOsmol/L
(calc) Sterile Nonpyrogenic Single
dose container Additives may be
incompatible Consult with pharmacist
if available When introducing
additives use aseptic technique Mix
thoroughly Do not store Dosage
Intravenously as directed by a
physician See directions Cautions
Squeeze and inspect inner bag which
maintains product sterility Discard if
leaks are found Must not be used in
series connections Do not administer
simultaneously with blood Do not
use unless solution is clear
Rx Only  Store at room temperature
(25oC/77oF) until ready to use Avoid
excessive heat See insert

Baxter Logo
Baxter Healthcare Corporation
Deerfield IL 60015 USA

Made in USA

Baxter AVIVA and the AVIVA
crescent design are trademarks of
Baxter International Inc

For product information
1-800-933-0303

AVIVA CONTAINER

Carton Label

6E0062

40-250 ML

AVIVA CONTAINER

5% Dextrose Injection, USP

EXP
XXXXX

SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX

LOT
XXXXX

PRIMARY BAR CODE
(01) 50303386346027

Container Label

LOT
EXP
500 mL
6E0163
NDC 0338-6347-03

10% Dextrose
Injection USP

Each 100 mL contains 10 g Dextrose Hydrous
USP pH 4.5 (3.2 to 6.5) Hypertonic Osmolarity
505 mOsmol/L (calc) Sterile Nonpyrogenic
Single dose container Additives may be
incompatible Consult with pharmacist if available
When introducing additives use aseptic technique
Mix thoroughly Do not store
Dosage Intravenously as directed by a physician
See directions Cautions Squeeze and inspect inner
bag which maintains product sterility Discard
if leaks are found Must not be used in series
connections Do not administer simultaneously
with blood Do not use unless solution is
clear Rx Only  Store at room temperature
(25oC/77oF) until ready to use Avoid excessive
heat See insert

Baxter Logo
Baxter Healthcare Corporation
Deerfield IL 60015 USA

Made in USA

Baxter AVIVA and the AVIVA
crescent design are trademarks of
Baxter International Inc

For product information
1-800-933-0303

AVIVA CONTAINER

Carton Label

6E0163

24-500 ML

AVIVA CONTAINER

10% Dextrose Injection, USP

EXP
XXXXX

SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX

LOT
XXXXX

PRIMARY BAR CODE
(01) 50303386347031

DEXTROSE 
dextrose monohydrate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0338-6346
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 50 g  in 1000 mL
Inactive Ingredients
Ingredient Name Strength
Water  
Packaging
# Item Code Package Description
1 NDC:0338-6346-02 250 mL in 1 BAG
2 NDC:0338-6346-03 500 mL in 1 BAG
3 NDC:0338-6346-04 1000 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA016673 03/04/1971
DEXTROSE 
dextrose monohydrate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0338-6347
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 100 g  in 1000 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
Packaging
# Item Code Package Description
1 NDC:0338-6347-02 250 mL in 1 BAG
2 NDC:0338-6347-03 500 mL in 1 BAG
3 NDC:0338-6347-04 1000 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA016694 01/25/1971
Labeler - Baxter Healthcare Corporation (005083209)
Establishment
Name Address ID/FEI Operations
Baxter Healthcare Corporation 059140764 ANALYSIS(0338-6346, 0338-6347), LABEL(0338-6346, 0338-6347), MANUFACTURE(0338-6346, 0338-6347), PACK(0338-6346, 0338-6347), STERILIZE(0338-6346, 0338-6347)
Revised: 01/2014
 
Baxter Healthcare Corporation
Hide
(web2)